United States & American Society of Clinical Oncology

United States: The studies discussed involve patients and practices within the United States>>> and address a significant health concern for American women.

American Society of Clinical Oncology: The American Society of Clinical Oncology>>> Annual Meeting served as the platform for presenting the significant research findings on GLP-1 receptor agonist and breast cancer prevention.

United States: The United States>>> was the location of the U.S.-led study of daraxonrasib and the initial application for drug licensing to the United States — Food and Drug Administration>>>.

American Society of Clinical Oncology: The American Society of Clinical Oncology meeting in Chicago was the venue where the significant findings of the daraxonrasib study were presented to the medical community.

United States: The United States will host the presentation of the study's findings at the American Society of Clinical Oncology's annual meeting in Chicago.

American Society of Clinical Oncology: The American Society of Clinical Oncology is hosting its annual meeting where the groundbreaking results of the OPTIMA trial are being presented, disseminating the findings to a global audience of cancer specialists.

United States: The United States hosted the American Society of Clinical Oncology Annual Meeting in Chicago, where the study results were presented.

American Society of Clinical Oncology: The American Society of Clinical Oncology hosted the annual meeting where the study results for SKB500 were presented, serving as a key platform for disseminating medical advancements.

United States: The United States is a key market for IBI363, with Innovent Biologics and Takeda Pharmaceutical Company co-commercializing the drug there. The U.S. FDA has granted Fast Track Designations for IBI363.

American Society of Clinical Oncology: The American Society of Clinical Oncology (ASCO) Annual Meeting is the platform where the updated clinical data for IBI363 was presented, providing a significant forum for disseminating these important findings to the medical and scientific community.

United States: The United States>>> is a key market for prostate cancer treatment, with a significant number of high-risk patients who could benefit from Apalutamide>>>.

American Society of Clinical Oncology: The American Society of Clinical Oncology>>> meeting served as the platform for presenting the groundbreaking trial data for Apalutamide>>>.

United States: United States>>> is one of the countries where patients were enrolled for the KEYNOTE-942 trial, contributing to the global scope of the research. Its involvement highlights its participation in international medical studies and its significant burden of skin cancer cases.

American Society of Clinical Oncology: The American Society of Clinical Oncology>>> is hosting the presentation of the trial results, solidifying its role as a central platform for disseminating significant cancer research. This event enhances its prestige and influence within the oncology community.

United States: The United States is relevant as the country where golidocitinib received Fast Track Designation from the United States — Food and Drug Administration (FDA).

American Society of Clinical Oncology: The American Society of Clinical Oncology (ASCO) Annual Meeting served as the platform for Dizal Pharmaceutical to present its clinical trial results, providing a credible forum for dissemination.

American Society of Clinical Oncology: The American Society of Clinical Oncology featured the study findings at its annual meeting, with its chief medical officer, Julie Gralow, endorsing the high quality of evidence presented.